ClinicalTrials.gg
CompletedNCT05387759Updated Apr 27, 2025

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

A Phase 1 interventional study of Aticaprant Supratherapeutic Dose and Aticaprant Therapeutic Dose in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effects of aticaprant on QT/ QT interval corrected for heart rate (HR) (QTc) intervals and electrocardiogram (ECG) morphology at therapeutic and supratherapeutic exposures in healthy adult participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy on the basis of physical examination, medical history, vital signs, and 12-lead (ECG) performed at screening and admission to the study center on Day -1 of the first treatment period. Minor abnormalities in ECG, which are not considered to be of clinical significance by the investigator, are acceptable
  • (BMI; weight [kilograms {kg}/ height square [meter square {m\^2}]) between 18 and 30.0 kg/m\^2 (inclusive), and body weight not less than 50 kg at screening
  • All female participants must have a negative serum pregnancy test (Beta-human chorionic gonadotropin [Beta-hCG]) at screening and a negative urine pregnancy test at admission to the study site on Day -1 of the first treatment period
  • A woman must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of at least 90 days after receiving the last dose of study intervention
  • Non-smoker (not smoked for 3 months prior to screening)

Exclusion criteria

Exclusion Criteria:

  • History of or current significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, lipid abnormalities, bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease, Parkinson's disease, infection, or any other illness that the investigator considers should exclude the participant
  • History of additional risk factors for Torsade de Pointes or the presence of a family history of short syndrome, long QT syndrome, sudden unexplained death at a young age (less than/equal to 40 years), drowning or sudden infant death syndrome in a first degree relative (that is, biological parent, sibling, or child)
  • Any skin condition likely to interfere with electrocardiographic electrode placement or adhesion
  • Breast implant or a history of thoracic surgery likely to cause abnormality of the electrical conduction through thoracic tissues
  • History of within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    Healthy participants will receive single oral dose of Aticaprant (Dose 1) (Treatment A) in Treatment Period 1, followed by Moxifloxacin (Dose 2) (Treatment D) in Treatment Period 2, followed by Aticaprant (Dose 3) (Treatment B) in Treatment Period 3 and then placebo (Treatment C) in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.

    Drug: Aticaprant Supratherapeutic Dose · Drug: Aticaprant Therapeutic Dose · Drug: Placebo · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 2

    Healthy participants will receive single oral dose of Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 and then Treatment D in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.

    Drug: Aticaprant Supratherapeutic Dose · Drug: Aticaprant Therapeutic Dose · Drug: Placebo · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 3

    Healthy participants will receive single oral dose of Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3 and then Treatment A in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.

    Drug: Aticaprant Supratherapeutic Dose · Drug: Aticaprant Therapeutic Dose · Drug: Placebo · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence 4

    Healthy participants will receive single oral dose of Treatment D in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 and then Treatment B in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7 to 15 days between each treatment period.

    Drug: Aticaprant Supratherapeutic Dose · Drug: Aticaprant Therapeutic Dose · Drug: Placebo · Drug: Moxifloxacin

Interventions

  • Aticaprant supratherapeutic dose capsule will be administered orally.

    Also known as: JNJ-67953964

  • Aticaprant therapeutic dose capsule will be administered orally.

    Also known as: JNJ-67953964

  • DrugPlacebo

    Placebo will be administered orally.

  • Moxifloxacin capsule will be administered orally.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in QTc at Each Time Point

    Change from baseline in QTc at each time point will be reported.

    Time frame: Baseline up to Day 4

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of Aticaprant

    Cmax is defined as the maximum observed plasma concentration of aticaprant and it's metabolite.

    Time frame: Predose up to 72 hours postdose (up to Day 4)

  2. Time To Reach The Maximum Observed Concentration of Aticaprant (Tmax)

    Tmax is the actual sampling time to reach the maximum observed plasma concentration of aticaprant.

    Time frame: Predose up to 72 hours postdose (up to Day 4)

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to last of Aticaprant (AUC [0-last])

    AUC (0-last) is the area under the plasma concentration-time curve from time 0 to the time of the last measurable (non-below quantification limit) concentration of aticaprant.

    Time frame: Predose up to 72 hours postdose (up to Day 4)

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time of Aticaprant (AUC[0-infinity])

    AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time of aticaprant.

    Time frame: Predose up to 72 hours postdose (up to Day 4)

  5. Number of Participants With Adverse Events (AEs)

    Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product.

    Time frame: Up to Day 4

  6. Number of Participants with AEs of Special Interest (AESI)

    Number of participants with AESIs will be reported. Pruritus and severe diarrhea is considered to be an AESI.

    Time frame: Up to Day 4

  7. Number of Participants With Change in Vital Signs

    Number of participants with change in vital signs will be reported. Body temperature, blood pressure, and pulse/heart rate (HR) measurements will be assessed.

    Time frame: Up to Day 4

  8. Number of Participants With Change in Laboratory Values

    Number of participants with change in laboratory parameters will be reported. Hematology, serum chemistry, and routine urinalysis will be assessed.

    Time frame: Up to Day 4

07

Study locations

1 site
  • Clinical Pharmacology Unit
    Merksem, 2170, Belgium
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Oct 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
May 24, 2022
StartActual
May 30, 2022
Primary completionActual
Oct 4, 2022
CompletionActual
Oct 4, 2022
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05387759
Responsible party
Sponsor
First posted
May 24, 2022
Start date
May 30, 2022
Primary completion
Oct 4, 2022
Completion
Oct 4, 2022
Last update
Apr 27, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aticaprant

Start the discussion